welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy
Antisense Therapeutics today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).
Commencement of the trial represents an important development milestone for the Company and for patients seeking better and safer treatments.
ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). DMD patients who have a greater number of T cells with high levels of CD49d on their surface have more severe and rapid disease progression.
rareRelated
-
AbCellera is enabling the translation of laboratory research to clinical application for fibrosis associated with co...Duchenne muscular dystrophy (DMD) is one...
-
Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Degeneration in Duchenne Muscular DystrophyThis is a pilot clinical trial to assess...
-
CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene ...CureDuchenne, a national venture phila...
-
Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in D...Santhera Pharmaceuticals announces that ...
-
User-centred Assistive System for Arm Functions in Neuromuscular SubjectsRestore a lost function is a special exp...
-
A Study of Tadalafil for Duchenne Muscular DystrophyThe main purpose of this study is to det...
-
There’s No Straight Line in Drug DevelopmentToday’s FDA disapproval of Sarepta’s...
-
Catabasis Quarterly: Updates on edasalonexent and clinical trialsWe are pleased to announce that we have ...
